MXCN Maxcyte Inc

MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced Company management will participate in the following investor conferences:

• Bank of America 2022 Healthcare ConferencePresentation on Wednesday, May 11th at 4:40 p.m. Pacific Time

• William Blair 42nd Annual Growth Stock conferenceFireside chat on Wednesday, June 8th at 9:20 a.m. Central Time

Live and archived webcasts of the events will be available on the “Events” section of the MaxCyte investor relations website at https://investors.maxcyte.com/.

About MaxCyte

MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation® platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™, and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.

MaxCyte Contacts:

US IR AdviserGilmartin GroupDavid Deuchler, CFA	+1 415-937-5400ir@maxcyte.com
Nominated Adviser and Joint Corporate BrokerPanmure GordonEmma Earl / Freddy CrossleyCorporate BrokingRupert Dearden	+44 (0)20 7886 2500
UK IR AdviserConsilium Strategic CommunicationsMary-Jane ElliottChris Welsh	+44 (0)203 709 5700maxcyte@consilium-comms.com